Errata (DOI:10.1016/S1473-3099(07)70159-7);Viral dynamics in transplant patients: implications for disease

Lancet Infectious Diseases

Volumn 7, Issue 7, 2007, Pages 460-472

  Funk, Georg A ^a   Gosert, Rainer ^a   Hirsch, Hans H ^a,b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; AZATHIOPRINE; CIDOFOVIR; CORTICOSTEROID; CYCLOSPORIN A; FOSCARNET; GANCICLOVIR; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PROTEINASE INHIBITOR; RIBAVIRIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADD ON THERAPY; ADENOVIRUS; BK VIRUS; CLEARANCE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; GRAFT RECIPIENT; HALF LIFE TIME; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS G; HEPATITIS G VIRUS; HERPES; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; IMMUNOSUPPRESSIVE TREATMENT; KINETICS; LIVER FIBROSIS; LOADING DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MATHEMATICAL MODEL; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSPLANTATION; VIRUS INFECTION; VIRUS LOAD;

EID: 34250725406     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(08)70225-1     Document Type: Erratum

References (87)

1. Oldstone M. Viruses can cause disease in the absence of morphological evidence of cell injury: implication for uncovering new diseases in the future. J Infect Dis 159 (1989) 384-389
2. Hirsch H. BK virus: opportunity makes a pathogen. Clin Infect Dis 41 (2005) 354-360
3. Perelson A. Modelling viral and immune system dynamics. Nat Rev Immunol 2 (2002) 28-36
4. Ho D., Neumann A., Perelson A., Chen W., Leonard J., and Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373 (1995) 123-126
5. Wei X., Ghosh S., Taylor M., et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373 (1995) 117-122
6. Perelson A., Neumann A., Markowitz M., Leonard J., and Ho D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271 (1996) 1582-1586
7. Nowak M., Bonhoeffer S., Hill A., Boehme R., Thomas H., and McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 93 (1996) 4398-4402
8. Whalley S., Murray J., Brown D., et al. Kinetics of acute hepatitis B virus infection in humans. J Exp Med 193 (2001) 847-854
9. Neumann A., Lam N., Dahari H., et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282 (1998) 103-107
10. Hirsch H. Virus infections post transplant: risk and immunity. Transpl Infect Dis 7 (2005) 97-98
11. Pereyra F., and Rubin R. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 17 (2004) 357-361
12. Bonhoeffer S., Funk G., Gunthard H., Fischer M., and Muller V. Glancing behind virus load variation in HIV-1 infection. Trends Microbiol 11 (2003) 499-504
13. Mellors J., Rinaldo Jr. C., Gupta P., White R., Todd J., and Kingsley L. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272 (1996) 1167-1170
14. Perelson A., Essunger P., Cao Y., et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387 (1997) 188-191
15. Finzi D., and Siliciano R. Taking aim at HIV replication. Nat Med 6 (2000) 735-736
16. Funk G., Fischer M., Joos B., et al. Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells. J Acquir Immune Defic Syndr 26 (2001) 397-404
17. Di Mascio M., Dornadula G., Zhang H., et al. In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 copies per milliliter, with a half-life of 6 months. J Virol 77 (2003) 2271-2275
18. Ho D. Toward HIV eradication or remission: the tasks ahead. Science 280 (1998) 1866-1867
19. Rosenberg E., Altfeld M., Poon S., et al. Immune control of HIV-1 after early treatment of acute infection. Nature 407 (2000) 523-526
20. Oxenius A., Price D., Easterbrook P., et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 97 (2000) 3382-3387
21. Markowitz M., Louie M., Hurley A., et al. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 77 (2003) 5037-5038
22. Smith L., Tonkin J., Lawson M., and Shellam G. Isolates of cytomegalovirus (CMV) from the black rat Rattus rattus form a distinct group of rat CMV. J Gen Virol 85 (2004) 1313-1317
23. Ghisetti V., Barbui A., Franchello A., et al. Quantitation of cytomegalovirus DNA by the polymerase chain reaction as a predictor of disease in solid organ transplantation. J Med Virol 73 (2004) 223-229
24. Emery V., Hassan-Walker A., Burroughs A., and Griffiths P. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and experienced immunocompromised hosts. J Infect Dis 185 (2002) 1723-1728
25. Emery V. Viral dynamics during active cytomegalovirus infection and pathology. Intervirology 42 (1999) 405-411
26. Mattes F., Hainsworth E., Hassan-Walker A., et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 191 (2005) 89-92
27. Smets F., Latinne D., Bazin H., et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 73 (2002) 1603-1610
28. Gärtner B., Schafer H., Marggraff K., et al. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol 40 (2002) 351-358
29. Orentas R., Schauer Jr. D., Ellis F., Walczak J., Casper J., and Margolis D. Monitoring and modulation of Epstein-Barr virus loads in pediatric transplant patients. Pediatr Transplant 7 (2003) 305-314
30. To E., Chan K., Leung S., et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res 9 (2003) 3254-3259
31. Boutolleau D., Fernandez C., Andre E., et al. Human herpesvirus (HHV)-6 and HHV-7: two closely related viruses with different infection profiles in stem cell transplantation recipients. J Infect Dis 187 (2003) 179-186
32. Dahari H., Major M., Zhang X., et al. Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology 128 (2005) 1056-1066
33. Ramratnam B., Bonhoeffer S., Binley J., et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 354 (1999) 1782-1785
34. Fukumoto T., Berg T., Ku Y., et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology 24 (1996) 1351-1354
35. Garcia-Retortillo M., Forns X., Feliu A., et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 35 (2002) 680-687
36. Berg T., Muller A., Platz K., et al. Dynamics of GB virus C viremia early after orthotopic liver transplantation indicates extrahepatic tissues as the predominant site of GB virus C replication. Hepatology 29 (1999) 245-249
37. Low J., Humes H., Szczypka M., and Imperiale M. BKV and SV40 infection of human kidney tubular epithelial cells in vitro. Virology 323 (2004) 182-188
38. Freimuth P. A human cell line selected for resistance to adenovirus infection has reduced levels of the virus receptor. J Virol 70 (1996) 4081-4085
39. Lankester A., van Tol M., Claas E., Vossen J., and Kroes A. Quantification of adenovirus DNA in plasma for management of infection in stem cell graft recipients. Clin Infect Dis 34 (2002) 864-867
40. Watzinger F., Suda M., Preuner S., et al. Real-time quantitative PCR assays for detection and monitoring of pathogenic human viruses in immunosuppressed pediatric patients. J Clin Microbiol 42 (2004) 5189-5198
41. Dixit N., Markowitz M., Ho D., and Perelson A. Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy. Antivir Ther 9 (2004) 237-246
42. Little S., McLean A., Spina C., Richman D., and Havlir D. Viral dynamics of acute HIV-1 infection. J Exp Med 190 (1999) 841-850
43. Lawson C. Cytomegalovirus after kidney transplantation: a case review. Prog Transplant 15 (2005) 157-160
44. Ljungman P., Griffiths P., and Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34 (2002) 1094-1097
45. Reinke P., Prosch S., Kern F., and Volk H. Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transpl Infect Dis 1 (1999) 157-164
46. Kim S., Varghese T., Zhang Z., et al. Renal ischemia/reperfusion injury activates the enhancer domain of the human cytomegalovirus major immediate early promoter. Am J Transplant 5 (2005) 1606-1613
47. Razonable R., van Cruijsen H., Brown R., et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis 187 (2003) 1801-1808
48. Humar A., Kumar D., Boivin G., and Caliendo A. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 186 (2002) 829-833
49. Anderson R., and May R. Infectious diseases of humans: dynamics and control (1991), Oxford University Press, Oxford
50. Lloyd A. The dependence of viral parameter estimates on the assumed viral life cycle: limitations of studies of viral load data. Proc Biol Sci 268 (2001) 847-854
51. Boivin G., Goyette N., Gilbert C., Humar A., and Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis 7 (2005) 166-170
52. Hanto D., Gajl-Peczalska K., Frizzera G., et al. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy. Ann Surg 198 (1983) 356-369
53. Walling D., Andritsos L., Etienne W., et al. Molecular markers of clonality and identity in Epstein-Barr virus-associated B-cell lymphoproliferative disease. J Med Virol 74 (2004) 94-101
54. Thorley-Lawson D., and Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350 (2004) 1328-1337
55. Preiksaitis J. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Clin Infect Dis 39 (2004) 1016-1023
56. Gustafsson A., Levitsky V., Zou J., et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95 (2000) 807-814
57. Hodgkin P., Lee J., and Lyons A. B cell differentiation and isotype switching is related to division cycle number. J Exp Med 184 (1996) 277-281
58. Wagner H., Fischer L., Jabs W., Holbe M., Pethig K., and Bucsky P. Longitudinal analysis of Epstein-Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by real-time polymerase chain reaction. Transplantation 74 (2002) 656-664
59. Storek J., Lalovic B., Rupert K., Dawson M., Shen D., and Maloney D. Kinetics of B, CD4 T, and CD8 T cells infused into humans: estimates of intravascular:extravascular ratios and total body counts. Clin Immunol 102 (2002) 249-257
60. Wang J., and Sugden B. Origins of bidirectional replication of Epstein-Barr virus: models for understanding mammalian origins of DNA synthesis. J Cell Biochem 94 (2005) 247-256
61. Laichalk L., Hochberg D., Babcock G., Freeman R., and Thorley-Lawson D. The dispersal of mucosal memory B cells: evidence from persistent EBV infection. Immunity 16 (2002) 745-754
62. Comoli P., Labirio M., Basso S., et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 99 (2002) 2592-2598
63. Comoli P., Maccario R., Locatelli F., et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 5 (2005) 1415-1422
64. Mizukawa Y., and Shiohara T. Virus-induced immune dysregulation as a triggering factor for the development of drug rashes and autoimmune diseases: with emphasis on EB virus, human herpesvirus 6 and hepatitis C virus. J Dermatol Sci 22 (2000) 169-180
65. De Clercq E., Naesens L., De Bolle L., Schols D., Zhang Y., and Neyts J. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Med Virol 11 (2001) 381-395
66. Neumann A., Lam N., Dahari H., et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 182 (2000) 28-35
67. Pawlotsky J. Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis 7 (2003) 45-66
68. Kamar N., Rostaing L., Selves J., et al. Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant 5 (2005) 1704-1712
69. Watashi K., Ishii N., Hijikata M., et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 19 (2005) 111-122
70. Powers K., Ribeiro R., Patel K., et al. Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl 12 (2006) 207-216
71. Ballardini G., De Raffele E., Groff P., et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl 8 (2002) 10-20
72. Karino Y., Toyota J., Sugawara M., et al. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 18 (2003) 404-410
73. Nickeleit V., Hirsch H., Binet I., et al. Polyomavirus infection of renal allograft recipients: from latent infection to manifest disease. J Am Soc Nephrol 10 (1999) 1080-1089
74. Knowles W., Pipkin P., Andrews N., et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71 (2003) 115-123
75. Hirsch H., and Steiger J. Polyomavirus BK. Lancet Infect Dis 3 (2003) 611-623
76. Binet I., Nickeleit V., Hirsch H., et al. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation 67 (1999) 918-922
77. Funk G., Steiger J., and Hirsch H. Rapid dynamics of polyomavirus type BK in renal transplant recipients. J Infect Dis 193 (2006) 80-87
78. Hirsch H., Knowles W., Dickenmann M., et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 347 (2002) 488-496
79. Randhawa P., Finkelstein S., Scantlebury V., et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 67 (1999) 103-109
80. Hirsch H. Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation. Am J Transplant 2 (2002) 25-30
81. Hirsch H., Drachenberg C., Steiger J., and Ramos E. Polyomavirus associated nephropathy in renal transplantation: critical issues of screening and management. Adv Exp Med Biol 577 (2006) 160-173
82. Hirsch H., Brennan D., Drachenberg C., et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 79 (2005) 1277-1286
83. Drachenberg C., Papadimitriou J., Hirsch H., et al. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant 4 (2004) 2082-2092
84. Randhawa P., Vats A., Zygmunt D., et al. Quantitation of viral DNA in renal allograft tissue from patients with BK virus nephropathy. Transplantation 74 (2002) 485-488
85. Jarvis L., Bell H., Simmonds P., et al. The effect of treatment with alpha-interferon on hepatitis G/GBV-C viraemia. The CONSTRUCT Group. Scand J Gastroenterol 33 (1998) 195-200
86. Alemany R., Suzuki K., and Curiel D. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 81 (2000) 2605-2609
87. Lion T., Baumgartinger R., Watzinger F., et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 102 (2003) 1114-1120